Based on the above multi-dimensional therapeutic effect, several clinical studies have shown that the implementation of PCSK9 inhibitors greatly reduces lipid levels and the occurrence of cardiovascular adverse events in patients with coronary heart disease (10, 12). This evidence concerns the gene PCSK9 and coronary artery disorder.